{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:37:36Z","timestamp":1795109856497,"version":"4.10.3"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24CA265879-01-1"],"award-info":[{"award-number":["U24CA265879-01-1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2024.12.007","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T04:31:21Z","timestamp":1737606681000},"page":"626-640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"87","author":[{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arifa","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneez Zahra Rubab","family":"Khakwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammad","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan K.","family":"Cobran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvan C.","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.12.007_b0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-019-0153-2","article-title":"Role of the DNA damage response in prostate cancer formation, progression and treatment","volume":"23","author":"Zhang","year":"2020","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2024.12.007_b0010","unstructured":"US Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Press release May 19, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer."},{"key":"10.1016\/j.eururo.2024.12.007_b0015","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. Press release May 15, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate."},{"key":"10.1016\/j.eururo.2024.12.007_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2024.12.007_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.12.007_b0030","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b9000","unstructured":"Riaz IB, Naqvi SAA, He H, Murad MH. Living interactive evidence (LIvE) synthesis framework. URL: https:\/\/living-evidence.com\/#sec-framework."},{"key":"10.1016\/j.eururo.2024.12.007_b0035","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.12.007_b0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Riaz","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.007_b0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0050","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.12.007_b0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.eururo.2024.12.007_b0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.007_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-4-17","article-title":"Meta-analytic methods for pooling rates when follow-up duration varies: a case study","volume":"4","author":"Guevara","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2024.12.007_b0070","volume":"vol. 12","author":"Kahn","year":"1989"},{"key":"10.1016\/j.eururo.2024.12.007_b0075","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.eururo.2024.12.007_b0080","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1017\/S2045796021000664","article-title":"The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note","volume":"30","author":"Cuijpers","year":"2021","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.eururo.2024.12.007_b0085","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.007_b0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0100","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2019.37.15_suppl.5005","article-title":"TOPARP-B: a phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations","volume":"37","author":"Mateo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0105","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.2021.39.6_suppl.27","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: results from the PROfound study","volume":"39","author":"Matsubara","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2020.38.6_suppl.134","article-title":"PROfound: efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","volume":"38","author":"Bono","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2021.39.6_suppl.126","article-title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound","volume":"39","author":"de Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0125","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.2021.39.6_suppl.93","article-title":"TALAPRO-1: phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"de Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0135","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2020.38.6_suppl.118","article-title":"Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): correlative measures of tumor response in phase II GALAHAD study","volume":"38","author":"Smith","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2019.37.7_suppl.202","article-title":"Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD","volume":"37","author":"Smith","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0150","doi-asserted-by":"crossref","first-page":"v884","DOI":"10.1093\/annonc\/mdz394.043","article-title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)","volume":"30","author":"Smith","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0155","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0160","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.12.007_b0165","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0170","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.007_b9005","unstructured":"Riaz IB, Naqvi SAA, He H, Murad MH. Living evidence for PARPi therapy in mCRPC patients. URL: https:\/\/parp.living-evidence.com\/."},{"key":"10.1016\/j.eururo.2024.12.007_b0175","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0180","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1093\/oncolo\/oyad008","article-title":"Niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: phase II QUEST study results","volume":"28","author":"Chi","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2024.12.007_b0185","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0200","article-title":"Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.2023.41.6_suppl.170","article-title":"Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: second interim analysis (IA2) of MAGNITUDE","volume":"41","author":"Efstathiou","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0215","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2023.41.16_suppl.5004","volume":"41","author":"Fizazi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2022.40.6_suppl.011","article-title":"PROpel: phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Saad","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0225","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2024.12.007_b0230","doi-asserted-by":"crossref","first-page":"S1495","DOI":"10.1016\/j.annonc.2022.10.194","article-title":"157O\u2003Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"33","author":"Oya","year":"2022","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0235","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/JCO.2022.40.16_suppl.5020","article-title":"Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2024.42.4_suppl.165","article-title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0245","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2024.42.4_suppl.136","article-title":"Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: genomic subgroups based on likelihood of BRCA or HRR gene alteration status","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.2024.42.4_suppl.178","article-title":"Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2","volume":"42","author":"Zschaebitz","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0255","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1200\/JCO.20.02246","article-title":"BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?","volume":"38","author":"Markowski","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0260","article-title":"Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer","volume":"5","author":"Taza","year":"2021","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.eururo.2024.12.007_b0265","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2024.12.007_b0270","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0275","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2024.12.007_b0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.007_b0285","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms18091886","article-title":"The role of PALB2 in the DNA damage response and cancer predisposition","volume":"18","author":"Nepomuceno","year":"2017","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.eururo.2024.12.007_b0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tibs.2011.10.002","article-title":"The ATM protein kinase and cellular redox signaling: beyond the DNA damage response","volume":"37","author":"Ditch","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.eururo.2024.12.007_b0295","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e17042","article-title":"Dual inhibition of PARP and ATR induces homologous recombination repair deficiency and leads to synthetic lethality in prostate cancer with CDK12 alteration","volume":"41","author":"Akamatsu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly[ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.12.007_b0305","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.12.007_b0310","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.12.007_b0315","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2024.12.007_b0320","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2024.12.007_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl9794","article-title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer","volume":"8","author":"Miao","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.eururo.2024.12.007_b0330","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","article-title":"Technical and biological constraints on ctDNA-based genotyping","volume":"7","author":"Herberts","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.eururo.2024.12.007_b0335","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2024.12.007_b0340","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.eururo.2024.12.007_b0345","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0350","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","article-title":"Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis","volume":"7","author":"Messina","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0355","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jncc.2024.05.005","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao","year":"2024","journal-title":"J Natl Cancer Center"},{"key":"10.1016\/j.eururo.2024.12.007_b0360","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0365","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1002\/cnr2.1334","article-title":"Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer","volume":"4","author":"Maeda","year":"2021","journal-title":"Cancer Rep"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.12.007_b0370","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2022.40.16_suppl.5018","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects","volume":"40","author":"Hussain","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.12.007_b0375","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382402760X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382402760X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T01:36:23Z","timestamp":1748655383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382402760X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S030228382402760X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}